In this issue of the European Journal of Internal Medicine Pomero et al. present their
systematic review and meta-analysis evaluating the early use of clopidogrel and ticagrelor
in addition to aspirin for the treatment of patients presenting with an acute non-cardioembolic
minor acute ischemic stroke or transient ischemic attack (TIA) [
[1]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- P2Y12 inhibitors plus aspirin for acute treatment and secondary prevention in minor stroke and high-risk transient ischemic attack: A systematic review and meta-analysis.Eur J Intern Med. 2022; 100: 49-58https://doi.org/10.1016/j.ejim.2022.03.017
- Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial.Lancet Neurol. 2007; 6: 961-969
- Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack.N Engl J Med. 2013; 369: 11-19
- Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.N Engl J Med. 2018; 379: 215-225
- Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.N Engl J Med. 2020; 383: 207-217
- Time to Retire the Concept of Transient Ischemic Attack.JAMA. 2022; 327: 813-814
- The 2020 breakthroughs in early secondary prevention: dual antiplatelet therapy versus single antiplatelet therapy.Curr Opin Neurol. 2021; 34: 45-54
- Five-year risk of stroke after TIA or minor ischemic stroke.N Engl J Med. 2018; 378: 2182-2190
- Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.Lancet Neurol. 2019; 18: 539-548
- CSPS.com Trial of Adding Cilostazol to Antiplatelet Therapy to Reduce Recurrent Stroke.Stroke. 2020; 51: 696-698
- High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis.J Neurol Sci. 2017; 376: 112-116
- Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA.N Engl J Med. 2021; 385: 2520-2530
- Rivaroxaban with or without aspirin in stable cardiovascular disease.N Engl J Med. 2017; 2017: 1319-1330
- Stroke outcomes in the COMPASS Trial.Circulation. 2019; 139: 1134-1145
- Novel drug targets for ischemic stroke identified through mendelian randomization analysis of the blood proteome.Circulation. 2019; 140: 819-830
- New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention.JAMA Neurol. 2020; 77: 1308-1317
Article info
Publication history
Published online: April 18, 2022
Accepted:
April 14,
2022
Received:
April 10,
2022
Identification
Copyright
© 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- P2Y12 inhibitors plus aspirin for acute treatment and secondary prevention in minor stroke and high-risk transient ischemic attack: A systematic review and meta-analysisEuropean Journal of Internal MedicineVol. 100
- PreviewStroke is a leading cause of mortality and disability worldwide [1] and approximately 20 to 25% of ischemic stroke are anticipated by transient ischemic symptoms [2]. The risk of ischemic stroke ranges from 3 to 15% in the 90 days after a transient ischemic attack (TIA) or a minor ischemic stroke [3,4]. Aspirin is known to reduce the risk of recurrent stroke by approximately 20% [5,6] and it is currently considered the antithrombotic drug of choice in non-cardioembolic stroke patients [7]. Indeed, in patients with non-cardioembolic ischemic stroke, aspirin is the most effective treatment to reduce the risk of stroke recurrence during the first 3 months, and it is the only antiplatelet drug that has shown to reduce the risk of recurrent disabling ischemic stroke [8].
- Full-Text
- Preview
